Merit Medical Systems, Inc. (MMSI)

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Merit Medical Systems, Inc. (MMSI)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Merit Medical Systems, Inc. (“Merit”  or the Company”) (NASDAQ: MMSI).The investigation concerns whether Merit and certain of its officers and/or directors have violated federal securities laws.

 

On July 25, 2019, post-market, Merit announced its financial and operating results for the second quarter of 2019.  The Company announced net income of $6.9 million, or $0.12 per share, compared to $10.9 million, or $0.21 per share for the same period in the prior year.  Merit’s Chairman and Chief Executive Officer, Fred P. Lampropoulos, cited “a number of factors affecting revenues and gross margins during the second quarter,” including “foreign exchange [and] slower than anticipated conversion and uptake of acquired products.”  On this news, Merit’s stock price fell $13.84 per share, or 25.24%, to close at $41.00 on July 26, 2019.

 

If you are aware of any facts relating to this investigation, or purchased Merit shares, you can learn more about the investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484

 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2019 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.